An in vivo genome‐wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer

An in vivo genome‐wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer

Paclitaxel is a common breast cancer drug; however, some tumors are resistant. The identification of biomarkers for paclitaxel resistance or sensitivity would enable the development of strategies to improve treatment efficacy. A genome‐wide in vivo shRNA screen was performed on paclitaxel‐treated mi...

Full description

Bibliographic Details
Main Authors: Mohammad Sultan, Jacob T. Nearing, Justin M. Brown, Thomas T. Huynh, Brianne M. Cruickshank, Emily Lamoureaux, Dejan Vidovic, Margaret L. Dahn, Wasundara Fernando, Krysta M. Coyle, Carman A. Giacomantonio, Morgan G.I. Langille, Paola Marcato
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:Molecular Oncology
Subjects:
breast cancer
paclitaxel
BCL6
shRNA screen
biomarkers
Online Access:https://doi.org/10.1002/1878-0261.12964

Internet

https://doi.org/10.1002/1878-0261.12964

Similar Items